Novartis’ Pluvicto supply ‘fully unconstrained,’ eyes manufacturing expansion
Novartis says that access to Pluvicto is now “fully unconstrained” as the pharma giant plans for manufacturing expansions to ensure a steady supply of the prostate cancer radiotherapy.
The company can supply Pluvicto to patients within two weeks of ordering, said Jeevan Virk, Novartis’ head of radioligand therapy therapeutic area strategy. And for next year, it predicts a “combined annual capacity target of at least 250,000 radioligand therapy doses” across its facilities, Virk told Endpoints News in an email.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
